A photo of William Seibel.

William L. Seibel, PhD

  • Member, Division of Oncology
  • Assistant Professor, UC Department of Pediatrics



I collaborate with various scientific groups in my research lab, but I primarily focus on oncology and experimental hematology research. I am mainly interested in the application of medicinal chemistry, virtual screening and cheminformatics. I also participate in projects across other disciplines and focus areas.

I received my doctorate in chemistry from Harvard University and then spent 19 years in the discovery field of migraine and antimicrobial drugs. From my experience in the pharmaceutical industry, I moved toward utilizing and optimizing the technology and tools that streamline efforts in drug design. For example, I led technology groups in protein modeling, computational chemistry, structural biology and combinatorial chemistry. I later served as a project manager for the University of Cincinnati Drug Discovery Center and direct the College of Medicine’s Compound Library.

I began working at the Cincinnati Children’s Hospital Medical Center in 2013, after more than 25 years of experience in the field of drug discovery. My role at the Cincinnati Children’s Hospital Medical Center has been to employ these tools and expertise to assist others in their research studies. I’ve always been interested in working with numerous collaborators and investigators to 1) identify the most effective methods of discovering biologically active small molecules and 2) advance these findings toward the clinic. My research has been published in numerous respected journals, including Oncotarget, PLoS ONE, Methods in Molecular Biology, Cell Chemical Biology and Nature Communications.


Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Azhar, M; Kincaid, Z; Kesarwani, M; Menke, J; Sweiterman, J; Ansari, S; Reaves, A; Ahmed, A; Shahzad, R; Khan, A; et al. Blood Advances. 2022.

Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'Brien, E; et al. Science Translational Medicine. 2022; 14.

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OH F; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; et al. Leukemia. 2022; 36:637-647.

Pharmacological clearance of misfolded rhodopsin for the treatment of RHO-associated retinitis pigmentosa. Liu, X; Feng, B; Vats, A; Tang, H; Seibel, W; Swaroop, M; Tawa, G; Zheng, W; Byrne, L; Schurdak, M; et al. FASEB Journal. 2020; 34:10146-10167.

IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models. Gasilina, A; Premnauth, G; Gurjar, P; Biesiada, J; Hegde, S; Milewski, D; Ma, G; Kalin, TV; Merino, E; Meller, J; et al. PLoS ONE. 2020; 15.

Diverse Chemical Scaffolds Enhance Oligodendrocyte Formation by Inhibiting CYP51, TM7SF2, or EBP. Allimuthu, D; Hubler, Z; Najm, FJ; Tang, H; Bederman, I; Seibel, W; Tesar, PJ; Adams, DJ. Cell Chemical Biology. 2019; 26:593-599.e4.

Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Allaway, RJ; Wood, MD; Downey, SL; Bouley, SJ; Traphagen, NA; Wells, JD; Batra, J; Melancon, SN; Ringelberg, C; Seibel, W; et al. Oncotarget. 2018; 9:15860-15875.

Compound C/Dorsomorphin: Its Use and Misuse as an AMPK Inhibitor. Dasgupta, B; Seibel, W. . 2018.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Jiang, X; Hu, C; Ferchen, K; Nie, J; Cui, X; Chen, C; Cheng, L; Zuo, Z; Seibel, W; He, C; et al. Nature Communications. 2017; 8.